Michael Fistek, DO
Internal Medicine · Akron, OHNPI 1770872863
Payments from drug & device makers
Across 183 payments — averaging $11.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$306
- Boehringer Ingelheim$222
- Amgen$213
- Pfizer$177
- AstraZeneca$154
- Merck$148
- plus $875 from 20 others
What the payments were for
- Food & beverage$2,095100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $306 |
| Boehringer Ingelheim | 21 | $222 |
| Amgen | 14 | $213 |
| Pfizer | 21 | $177 |
| AstraZeneca | 6 | $154 |
| Merck | 16 | $148 |
| GSK | 17 | $139 |
| Novartis | 6 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Johnson & Johnson | 6 | $74 |
| Amarin Pharma, Inc. | 5 | $68 |
| Lilly USA, LLC | 5 | $65 |
| AbbVie(2 entities) | 4 | $56 |
| Coloplast | 1 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $52 |
| Astellas Pharma US Inc | 3 | $45 |
| Genentech USA, Inc. | 1 | $22 |
| Exact Sciences | 1 | $22 |
| Qiagen, LLC | 1 | $21 |
| Shire North American Group Inc | 1 | $21 |
| Mannkind Corporation | 1 | $18 |
| Bausch Health US, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Circassia Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
How this compares
$2,095 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 160 | $147,699 |
| JardianceEmpagliflozin | 108 | $109,466 |
| JanuviaSitagliptin Phosphate | 67 | $74,545 |
| RybelsusSemaglutide | 53 | $68,688 |
| XareltoRivaroxaban | 48 | $51,108 |
| MyrbetriqMirabegron | 75 | $43,217 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $41,724 |
| OzempicSemaglutide | 27 | $35,345 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 36 | $34,492 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $29,414 |
| ProliaDenosumab | 17 | $28,923 |
| FarxigaDapagliflozin Propanediol | 25 | $28,751 |
| TradjentaLinagliptin | 25 | $20,541 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $18,015 |
| QuliptaAtogepant | 16 | $16,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Spiriva Respimat | $222 | $148,388158 claims |
| PfizerEliquis | $177 | $147,699160 claims |
| Novo NordiskRybelsus, Ozempic, Xultophy 100-3.6 | $306 | $138,525116 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $139 | $89,153115 claims |
| MerckJanuvia | $148 | $74,54567 claims |
| Johnson & JohnsonXarelto | $74 | $51,10848 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $43,21775 claims |
| AmgenProlia | $213 | $28,92317 claims |
| AstraZenecaFarxiga | $154 | $28,75125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $65 | $27,95328 claims |
| AbbVieQulipta, Linzess | $56 | $26,37527 claims |
| NovartisEntresto | $77 | $14,76711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Akron
- Hassan MalikAkron$1.7M
- Jeffrey KleinAkron$833K
- Amy HiteAkron$305K
- Mark ArredondoAkron$215K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.